Last updated: July 22, 2026
Pfizer Inc. v. Sun Pharmaceutical Industries Ltd. (1:22-cv-01501): Litigation Summary, Patent-Scope Analysis, and Generic-Risk Outlook
What is Pfizer Inc. v. Sun Pharmaceuticals Industries Ltd., 1:22-cv-01501?
Case: Pfizer Inc. v. Sun Pharmaceutical Industries Ltd.
Docket: 1:22-cv-01501
Court level: U.S. federal court (district court docket format indicates U.S. District Court, but the specific district is not provided in the input).
Parties: Pfizer Inc. (plaintiff) vs. Sun Pharmaceutical Industries Ltd. (defendant).
Claims typically asserted in this case type: patent infringement under 35 U.S.C. § 271 related to an FDA-described generic (or other competitor) entry, commonly tied to an ANDA or Paragraph IV certification.
The user-provided input contains only the case caption and docket number. It does not include the asserted patents, the listed drug product, the asserted Orange Book patents, the filing date, the court, the complaint or amended complaint details, or the procedural posture needed to produce an accurate litigation summary and analysis.
What patents does Pfizer assert against Sun in 1:22-cv-01501?
A litigation “summary and analysis” requires, at minimum, the specific asserted patent numbers, claims asserted, use-based vs. composition vs. formulation vs. manufacturing theories, and which FDA reference listed drug the Orange Book listing corresponds to. Those facts are not present in the input.
What is the procedural status of the case (motions, rulings, settlement, or trial)?
A procedural timeline requires the record events (e.g., complaint filing date, answer, claim construction order, summary judgment, preliminary injunction motions, dismissal, or settlement agreement). None of these events are provided in the input.
How do Paragraph IV certifications typically drive the litigation in this docket?
In Pfizer vs. generic manufacturers cases, the usual driver is an FDA ANDA referencing a Pfizer NDA/RLD and certifying to one or more Orange Book patents as invalid, not infringed, or unenforceable (Paragraph IV). Litigation then proceeds under the Hatch-Waxman framework.
The asserted FDA listing, the ANDA number, the certification(s), and which patents were challenged are not provided in the input, so an accurate claim-by-claim or risk-by-risk analysis cannot be produced.
How strong is Pfizer’s patent estate based on infringement allegations and claim constructions?
Strength depends on:
- Whether patents are composition, method-of-use, formulation, or process patents
- Claim construction outcomes
- Expert testimony themes and non-infringement defenses
- Whether any patents are found invalid or narrowed
No patent numbers or court rulings are provided in the input.
What generic entry risks exist for Sun based on this litigation?
Entry risk depends on:
- Whether the court granted any injunction
- Whether Sun received FDA approval during/after litigation
- Whether any asserted patents were narrowed, stayed, or invalidated
None of these facts are in the input.
How does this compare with other Pfizer vs. Sun patent litigations?
Comparison requires a list of other dockets and outcomes, plus the drug/asset overlap. No asset or asserted drug is provided here.
What is the Orange Book status for the asserted Pfizer patents?
Orange Book status is necessary to map the legal claims to statutory exclusivity and potential design-around space. Orange Book listing data (patent numbers, expiration dates, exclusivity codes) is not provided.
What settlement terms are known (if any) and how do they affect launch timing?
Settlement terms (e.g., no-approval/no-launch commitments, carve-outs, permitted launch dates) require the settlement agreement details or docket entries stating those terms. None are provided.
What is the litigation impact on Pfizer revenue exposure?
Revenue exposure is driven by:
- Expected generic launch date absent litigation
- Market share and label volume for the RLD
- Probability-weighted duration of exclusivity and injunctions
None of this is available from the input alone.
Key Takeaways
- The input provides only the case caption and docket number.
- A “litigation summary and analysis” requires asserted patent numbers, the drug product/Orange Book listings, procedural history, and any court orders or settlement terms.
- Those core litigation facts are not present, so producing a complete, accurate summary would require sourcing docket filings and associated filings, which are not included in the provided information.
FAQs
- What information is required to summarize a Pfizer v. Sun Hatch-Waxman case accurately?
- How do asserted composition vs. method-of-use claims change generic design-around risk?
- What docket events most strongly predict final launch timing in Paragraph IV litigation?
- How does claim construction typically shift infringement outcomes in patent cases tied to ANDA Paragraph IV filings?
- Which Orange Book listings (drug substance, drug product, method-of-use) usually drive the longest litigation timelines?
References
(No sources were provided in the input; no citations can be produced without case filings, court orders, or FDA/Orange Book records.)
